Phase Ib/II Multicenter Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Phase of Trial: Phase I/II
Latest Information Update: 10 Aug 2018
Price : $35 *
At a glance
- Drugs Buparlisib (Primary) ; Carboplatin; Lomustine
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 08 Aug 2016 Status changed from active, no longer recruiting to completed.
- 08 Jul 2016 Planned End Date changed from 1 Apr 2016 to 1 Aug 2016.
- 08 Jul 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Aug 2016.